Total Payments
$700,525
2022 Payments
$820.00
Companies
8
Transactions
1,295
Medicare Patients
277
Medicare Billing
$41,740
Payment Breakdown by Category
Other$532,402 (76.0%)
Travel$95,194 (13.6%)
Consulting$46,169 (6.6%)
Food & Beverage$16,581 (2.4%)
Research$10,180 (1.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $494,527 | 294 | 70.6% |
| Travel and Lodging | $95,194 | 604 | 13.6% |
| Consulting Fee | $46,169 | 20 | 6.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $37,750 | 20 | 5.4% |
| Food and Beverage | $16,581 | 348 | 2.4% |
| Unspecified | $10,180 | 8 | 1.5% |
| Honoraria | $125.00 | 1 | 0.0% |
Payments by Type
General
$690,345
1,287 transactions
Research
$10,180
8 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eisai Inc. | $343,475 | 515 | $0 (2021) |
| UCB, Inc. | $210,120 | 485 | $0 (2022) |
| LivaNova USA, Inc. | $90,430 | 171 | $0 (2020) |
| Cyberonics, Inc. | $25,395 | 51 | $0 (2017) |
| UCB SA | $21,662 | 50 | $0 (2020) |
| UCB Biosciences Inc. | $9,304 | 21 | $0 (2019) |
| Lundbeck LLC | $125.00 | 1 | $0 (2017) |
| Sunovion Pharmaceuticals Inc. | $12.16 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2022 | $820.00 | 1 | UCB, Inc. ($820.00) |
| 2021 | $6,145 | 7 | Eisai Inc. ($3,895) |
| 2020 | $37,724 | 64 | Eisai Inc. ($15,431) |
| 2019 | $177,831 | 314 | EISAI INC. ($72,786) |
| 2018 | $183,187 | 290 | Eisai Inc. ($120,125) |
| 2017 | $294,817 | 619 | Eisai Inc. ($131,239) |
All Payment Transactions
1,295 individual payment records from CMS Open Payments — Page 1 of 52
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/14/2022 | UCB, Inc. | — | — | Cash or cash equivalent | $820.00 | Research |
| Study: A MULTICENTER, OPEN-LABEL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LACOSAMIDE IN NEONATES WITH R | ||||||
| 04/08/2021 | UCB, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| 03/31/2021 | UCB, Inc. | Briviact (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 03/18/2021 | UCB, Inc. | Briviact (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 01/26/2021 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Neurology | ||||||
| 01/26/2021 | Eisai Inc. | Fycompa (Drug) | Travel and Lodging | Cash or cash equivalent | $54.88 | General |
| Category: Neurology | ||||||
| 01/12/2021 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 01/06/2021 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 12/17/2020 | UCB, Inc. | Briviact (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 12/10/2020 | UCB, Inc. | Briviact (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Neurology | ||||||
| 12/07/2020 | UCB SA | — | Consulting Fee | Cash or cash equivalent | $3,280.00 | General |
| 11/12/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 10/29/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 10/21/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 10/14/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 10/12/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 09/24/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 09/22/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $720.00 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,000.00 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Travel and Lodging | Cash or cash equivalent | $328.39 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Travel and Lodging | Cash or cash equivalent | $170.78 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Travel and Lodging | Cash or cash equivalent | $16.00 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug) | Travel and Lodging | Cash or cash equivalent | $15.00 | General |
| Category: Neurology | ||||||
| 09/11/2020 | Eisai Inc. | Fycompa (Drug), Banzel | Food and Beverage | Cash or cash equivalent | $14.83 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, OPEN-LABEL, RANDOMIZED, PARALLEL-GROUP, ACTIVE-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF BRIVARACETAM ADMINISTERED INTRAVENOUSLY AS TREATMENT FOR INCREASED SEIZURE ACTIVITY IN AN EPILEPSY MONITORING UNIT SETTING PHASE 2 | UCB, Inc. | $3,120 | 2 |
| BRV DDI Review | UCB, Inc. | $2,300 | 1 |
| Efficacy and safety of brivaracetam for partial-onset seizures in three pooled clinical studies. | UCB, Inc. | $2,300 | 1 |
| A MULTICENTER, OPEN-LABEL, RANDOMIZED, ACTIVE COMPARATOR STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LACOSAMIDE IN NEONATES WITH R | UCB, Inc. | $820.00 | 1 |
| Efficacy of adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures at baseline: pooled results from long-term follow-up studies | UCB, Inc. | $800.00 | 1 |
| A review of the drug interactions of the new antiepileptic drug brivaracetam | UCB, Inc. | $420.00 | 1 |
| Adjunctive brivaracetam in patients with secondarily generalized tonic-clonic seizures at baseline: pooled results from long-term follow-up studies | UCB, Inc. | $420.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2021 | 3 | 47 | 62 | $23,266 | $6,036 |
| 2020 | 9 | 230 | 329 | $137,530 | $35,704 |
Total Patients
277
Total Services
391
Medicare Billing
$41,740
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 12 | 24 | $15,120 | $3,936 | 26.0% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2021 | 12 | 12 | $4,896 | $1,226 | 25.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 23 | 26 | $3,250 | $873.87 | 26.9% |
| 95720 | Continuous measurement of brain wave activity with video (veeg), 12-26 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 66 | 146 | $91,980 | $24,301 | 26.4% |
| 95718 | Continuous measurement of brain wave activity with video (veeg), 2-12 hours, with health care professional analysis, interpretation and report | Facility | 2020 | 33 | 33 | $13,464 | $3,575 | 26.6% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 39 | 53 | $10,229 | $2,595 | 25.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 21 | 22 | $6,028 | $1,644 | 27.3% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 12 | 12 | $5,004 | $1,154 | 23.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 21 | 25 | $3,125 | $780.13 | 25.0% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Facility | 2020 | 11 | 11 | $2,915 | $655.46 | 22.5% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 15 | 15 | $2,745 | $532.38 | 19.4% |
| 95816 | Measurement and recording of brain wave (eeg) activity, awake and drowsy | Facility | 2020 | 12 | 12 | $2,040 | $467.22 | 22.9% |
About Dr. Brian Moseley, MD
Dr. Brian Moseley, MD is a Neurology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1407010382.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Moseley, MD has received a total of $700,525 in payments from pharmaceutical and medical device companies, with $820.00 received in 2022. These payments were reported across 1,295 transactions from 8 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($494,527).
As a Medicare-enrolled provider, Moseley has provided services to 277 Medicare beneficiaries, totaling 391 services with total Medicare billing of $41,740. Data is available for 2 years (2020–2021), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology
- Other Specialties Neurology, Clinical Neurophysiology
- Location Cincinnati, OH
- Active Since 07/10/2008
- Last Updated 11/13/2017
- Taxonomy Code 2084N0400X
- Entity Type Individual
- NPI Number 1407010382
Products in Payments
- Fycompa (Drug) $343,475
- Briviact (Drug) $208,599
- VNS Therapy (Device) $115,825
- Vimpat (Drug) $8,929
- SABRIL (Drug) $125.00
- APTIOM (Drug) $12.16
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology Doctors in Cincinnati
Aram Zabeti, M.d, M.D
Neurology — Payments: $1.5M
Neurology $1.5M
Dr. Hope O'brien, Md, MD
Neurology — Payments: $530,605
Neurology $530,605
Alberto Espay, Md, MD
Neurology — Payments: $448,360
Neurology $448,360
Mrs. Susan Hibbs, Md, MD
Neurology — Payments: $255,533
Neurology $255,533
Zainab Contractor, Md, MD
Neurology — Payments: $212,716
Neurology $212,716
Reena Shah, Md, MD
Neurology — Payments: $173,678
Neurology $173,678